EU guidance could jeopardise confidentiality, says industry, but consumers want more openness
This article was originally published in SRA
Executive Summary
Draft European guidance on the kind of information that can be released from drug approval dossiers has received a predictably mixed response from pharmaceutical industry and public interest bodies1,2.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.